A Phase 2 study of Docetaxel and Bevacizumab as the second line treatment for patients with non-squamous non-small cell lung cancer previously treated with platinum-based chemotherapy.

A Phase 2 study of Docetaxel and Bevacizumab as the second line treatment for patients with non-squamous non-small cell lung cancer previously treated with platinum-based chemotherapy. - A Phase 2 study of Docetaxel and Bevacizumab as the second line treatment for patients with non-squamous non-small cell lung cancer previously treated with platinum-based chemotherapy.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006641

Enrollment

Registered

2011-11-07

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-squamous non-small cell lung cancer

Interventions

Docetaxel+Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Histologically or cytologically confirmed non-squamous non-small cell lung cancer 2.Stage 3/4 unresectable or unsuitable for radical irradiation 3.Relapsed or progressed to one prior chemotherapy 4. The prior chemotherapy is only one regimen. 5. With measurable disease (based on RECIST ver1.1) 6. Age >= 20 7. Performance status (ECOG) : 0 or 1, 2 8. Adequate function of vital organs as following;(within two weeks before registration) Neutrophils >= 1,500/mm3 Platelets >= 100,000/mm3 Hemoglobin >= 8.5 g/dL AST/ALT <= 2.5ULN Total bilirubin <= 1.5mg/dL Serum creatinine <= 1.5mg/dL PaO2 >= 60mmHg or SpO2 >= 92% 9. A life expectancy of more than 3 months 10. Written informed consent before initiation of study-related procedures

Exclusion criteria

Exclusion criteria: 1. No prior treatment with Docetaxel and Bevacizumab 2.History of hemoptysis with 2.5mL per time or more. 3.Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 4.massive pleural or pericardial effusion. 5. CNS metastasis 6. Patients with a concomitant or prior invasive malignancy who have had any evidence of the disease within the last 5 years 7. Patients with severe complications Unstable angina. cardiovascular disease, severe heart disease, heart failure within 3month. Uncontrollable diabetes mellitus and hypertension Active infection 8. In pregnancy, during breast feeding, or possibility of pregnancy. 9.The past history of severe allergic reactions 10. psychiatric patients 11. Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

Design outcomes

Primary

Measure	Time frame
Response Rate	—

Secondary

Measure	Time frame
Safety, Progression Free Survival	—

Countries

Japan

Contacts

Public ContactYusaku Akashi

Kinki University Faculty of Medicine, Nara Hospital Department of Medical Oncology

0743770880

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026